Myocardial Perfusion in Cardiac Amyloidosis
Liza Chacko(The Royal Free Hospital), Marianna Fontana(Johnson & Johnson (United States)), James Moon(Virginia Mason Medical Center), Daniel Knight(MACOM (United States)), Peter Kellman(National Institutes of Health), Helen J. Lachmann(Royal Free London NHS Foundation Trust), Mattia Riefolo(Azienda USL di Bologna), Ashutosh Wechelakar(MACOM (United States)), Lucia Venneri(MACOM (United States)), Philip N. Hawkins(The Royal Free Hospital), James Brown(MACOM (United States)), Tim Lockie(Royal Free London NHS Foundation Trust), Charlotte Manisty(National Institutes of Health), Janet A. Gilbertson(Children's Cancer and Leukaemia Group), Rishi Patel(MACOM (United States)), Kristopher Knott(University College London), Julian D. Gillmore(Alnylam Pharmaceuticals (United States)), Hui Xue(National Institutes of Health), Carol Whelan(Boston University), Yousuf Razvi(MACOM (United States)), Aldostefano Porcari(University of Trieste), Tushar Kotecha(Royal Society), Ornella Leone(Policlinico S.Orsola-Malpighi), Ana Martinez–Naharro(Children's Cancer and Leukaemia Group), Roby Rakhit(Royal Free London NHS Foundation Trust), Markella Ponticos(The Royal Free Hospital), Niket Patel(Royal Free London NHS Foundation Trust), Adam Ioannou(MACOM (United States)), Paolo Massa(MACOM (United States)), Arantxa González(Instituto de Salud Carlos III)
Cited by 40
Related Papers
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|2.9k
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
|Circulation|2016|2k
NALP3 Forms an IL-1β-Processing Inflammasome with Increased Activity in Muckle-Wells Autoinflammatory Disorder
|Immunity|2004|1.7k
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|1.4k